Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients

NCT00410930 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergy

Interventions

BIOLOGICAL: Subcutaneous immunotherapy - Recombinant birch pollen

Sponsor

Stallergenes Greer